Updates from the EMBRACA trial for advanced breast cancer
Updates from the EMBRACA trial for advanced breast cancer
Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer
Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer
Updates in head and neck cancers
KEYNOTE022: Triplet therapy for BRAF melanoma
First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
ESMO 2018: Melanoma highlights
IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy
KEYNOTE048: First line pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma
ESMO 2018: Highlights
IMpassion 130 trial results: Immunotherapy for metastatic breast cancer
The TRIBE-2 study for colorectal cancer